Update on safety and long-term outcomes in lenalidomide (LEN)-treated patients with red blood cell (RBC) transfusion-dependent Low-/Int-1-risk myelodysplastic syndromes (MDS) and DEL(5q)

Category Primary study
JournalHaematologica
Year 2012
This article has no abstract
Epistemonikos ID: cee0c14043a3049610f89ba2ef14334ec568cce6
First added on: Feb 06, 2025